William Blair Downgrades Neumora Therapeutics (NASDAQ:NMRA) to Market Perform
William Blair lowered shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from an outperform rating to a market ...
Fintel on MSN4d
Guggenheim Downgrades Neumora Therapeutics (NMRA)
Fintel reports that on March 10, 2025, Guggenheim downgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Buy ...
Le Lézard1d
Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. . Shareholders who purchased shares ...
Le Lézard1d
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
Wilson Encourages Investors Who Suffered Losses In Neumora To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Neumora pursuant and/or ...
NMRA ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Class Action Lawsuit Against Neumora Therapeutics, Inc. (NMRA)
Detailed price information for Neumora Therapeutics Inc (NMRA-Q) from The Globe and Mail including charting and trades.
Morningstar6d
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
NEW YORK, March 08, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Neumora Therapeutics, Inc. (“Neumora” or ...
The Globe and Mail5d
NMRA ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Class Action Lawsuit Against Neumora Therapeutics, Inc. (NMRA)
The complaint alleges that, in the Offering Documents, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) in order for Neumora to justify conducting ...
Mizuho Securities Keeps Their Hold Rating on Immunocore Holdings (IMCR)
In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Hold rating on Immunocore Holdings (IMCR – Research Report), ...
Stifel Nicolaus Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today and set a price target of ...